Boston Scientific Corporation
BSXBusiness Overview
ticker: BSX step: 01 generated: 2026-05-12 source: quick-research
Boston Scientific Corporation (BSX) — Business Overview
Business Description
Boston Scientific is the world's fastest-growing major medical device company, with FY2025 revenue of $20.1B (+19.9%) — by far the highest organic growth rate among large-cap medtech (vs. Medtronic mid-single-digit, J&J MedTech mid-single-digit, Stryker high-single-digit). Growth is led by the electrophysiology franchise anchored by FARAPULSE Pulsed Field Ablation (PFA) — the fastest-adopted cardiovascular device of the past decade — and Watchman left atrial appendage closure. BSX has positioned itself as the leader in two of medtech's fastest-growing categories: atrial fibrillation ablation and stroke prevention from afib.
Revenue Model
Two reportable segments:
- MedSurg (~$10B, growing ~+10%) — Endoscopy + urology + neuromodulation:
- Endoscopy (~$3.5B+) — GI endoscopy, pulmonary, advanced bronchoscopy.
- Urology (~$2.5B) — Stone management, urology services, peripheral.
- Neuromodulation (~$1B) — Pain management, deep brain stimulation, spinal cord stim.
- Cardiovascular (~$10B+, growing ~+23%) — Three sub-franchises:
- Cardiology (~$5B+) — Includes Watchman ($2B+ run-rate; +28% YoY).
- Electrophysiology (~$3.4B annualized) — FARAPULSE PFA, mapping catheters, ablation.
- Peripheral Interventions + structural heart + coronary stents.
Revenue mix is overwhelmingly recurring (consumables, single-use devices, capital-attached); EP segment is the highest-growth driver and the most concentrated competitive focus.
Products & Services
- FARAPULSE PFA: Pulsed field ablation system for atrial fibrillation; FDA-approved 2024; ~$1B+ revenue in first 12 months (fastest cardiovascular device launch in a decade). Expanded label for persistent AF (July 2025).
- Faraflex PFA + Farapoint PFA: Next-generation PFA catheters with improved workflow + mapping integration.
- Watchman FLX: Left atrial appendage closure device for AF stroke prevention; +28.4% growth FY25; $2B+ franchise.
- Endoscopy: GI navigators, hemostasis, dilation, biopsy, advanced bronchoscopy.
- Urology: Kidney stone management (LithoVue), prostate hyperplasia, men's health.
- Neuromodulation: WaveWriter SCS (spinal cord stim), Vercise DBS, Precision spinal cord stim.
- Peripheral Interventions: PAD treatment, drug-coated balloons, atherectomy, stents.
- Coronary: Drug-eluting stents (Synergy XD), balloon angioplasty.
- Cardiac Rhythm Management: Pacemakers, defibrillators (smaller share vs. MDT/ABT).
- Structural Heart: Acurate transcatheter aortic valve (TAVR — late entrant), Eluvia stent.
Customer Base & Go-to-Market
- Hospitals + cardiac centers: Electrophysiology labs (~5,000+ globally), interventional cardiology, structural heart programs.
- Ambulatory Surgery Centers (ASCs): Endoscopy + urology procedures increasingly moving to ASCs.
- GI specialists: ~16,000+ US gastroenterologists for endoscopy products.
- Pain management physicians: Neuromodulation customer base.
Geographic mix: ~60% US, ~40% international. Significant growth in Asia-Pacific + Europe for EP.
Competitive Position
BSX has emerged as the clear leader in electrophysiology PFA, having significantly outpaced Medtronic's PulseSelect, Johnson & Johnson Biosense Webster Varipulse, and Abbott (small EP presence). Structural advantages:
- FARAPULSE first-mover PFA + best clinical data — AVANT GUARD trial showed statistical superiority over antiarrhythmic drugs; market preference firmly with Farapulse.
- Watchman franchise compounding at 28%+ — AF treatment + stroke prevention bundle creates cross-sell with EP.
- Bolt Medical acquisition — Intravascular lithotripsy (IVL) entry; competes with Shockwave (now Johnson & Johnson MedTech).
- SoniVie acquisition — Renal denervation hypertension treatment platform.
- R&D + clinical trial leadership — Multiple Phase 3 + pivotal trials simultaneously running across EP + structural heart + endoscopy.
Competitive challenges:
- Medtronic — Major Cardiac Rhythm Management franchise + Affera EP acquisition (still smaller scale).
- Johnson & Johnson MedTech (Biosense Webster + Shockwave) — Direct EP + IVL competition.
- Abbott — Newer Volt PFA entry; smaller but well-funded.
- PFA category competition increasing — Affera (Medtronic), Varipulse (J&J), PulseSelect (MDT). Market share at 35–38% currently but defensible with Faraflex / Farapoint.
Key Facts
- Founded: 1979
- Headquarters: Marlborough, Massachusetts
- Employees: ~50,000
- Exchange: NYSE
- Sector / Industry: Health Care / Medical Devices
- Market Cap: ~$165B
- FY2025 Revenue: $20.074B (+19.9% reported)
- FY2025 Organic Growth: ~+15%
- FARAPULSE Revenue (Year 1): >$1B
- Watchman Franchise Annual Run-rate: ~$2B+
- Major Recent Acquisitions: Bolt Medical (IVL), SoniVie (renal denervation), Axonics (~$3.7B, sacral neuromodulation 2024)
- Dividend: None (growth focus)
- Q4 2025 Cardiovascular Growth: +23.2%
Financial Snapshot
ticker: BSX step: 04 generated: 2026-05-12 source: quick-research
Boston Scientific Corporation (BSX) — Financial Snapshot
Income Statement Summary
| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|---|---|---|---|---|
| Net Sales | $14.2B | $16.75B | $20.07B | +19.9% reported / +15.8% organic |
| Adjusted Operating Margin | 25.6% | 26.7% | 27.5% | +80 bps |
| Adjusted EPS | $2.05 | $2.51 | $3.10 | +24% |
Segment Detail (FY2025)
| Segment | FY25 Revenue | YoY |
|---|---|---|
| Cardiovascular | $13.3B | +23.2% |
| - Electrophysiology (FARAPULSE) | ~$3.4B annualized | +37% (Q4); >$1B in FARAPULSE Year 1 |
| - Watchman | ~$2.0B | +28% |
| - Cardiology + Peripheral + Coronary | ~$7B+ | mid-teens |
| MedSurg | ~$6.8B | +10% |
| - Endoscopy | ~$3.5B | +mid-single-digit |
| - Urology | ~$2.5B | high-single-digit |
| - Neuromodulation | ~$1B | mid-single-digit |
FY2026 Guidance (Revised April 2026 post Q1)
| Metric | 2026 Guide |
|---|---|
| Reported Sales Growth | +10.5–11.5% (initial Feb) → adjusted post-Q1 |
| Organic Sales Growth | +6.5–8.0% (revised down from 10–11%) |
| Adjusted Operating Margin Expansion | +50–75 bps |
| Adjusted EPS | $3.34–3.41 (+9–11%, revised down from $3.43–3.49) |
| Free Cash Flow | ~$4B (revised down from $4.2B) |
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$4.5B |
| Free Cash Flow | ~$3.7B |
| Capital Expenditures | ~$0.8B |
| Cash & Marketable Securities | ~$2B |
| Total Debt | ~$9B |
| Net Debt | ~$7B |
| Net Debt / EBITDA | ~1.3x |
| Dividend | None |
Key Ratios (approximate)
- P/E: ~34x (FY26 adjusted EPS midpoint) | EV/EBITDA: ~25x | FCF Yield: ~2.4%
- Revenue Growth (FY25): +19.9% reported, +15.8% organic
- Adjusted Operating Margin: 27.5%
- Net Debt / EBITDA: ~1.3x
- No dividend; growth-stock profile
Growth Profile
FY25 was a banner year — fastest growth in the major medtech peer group:
- Reported revenue +19.9%; organic +15.8%
- Electrophysiology (FARAPULSE) $3.4B annualized run-rate, fastest cardiovascular device launch in a decade
- Watchman LAAC franchise +28% YoY
- Adjusted operating margin expanded 80 bps to 27.5%
- Adjusted EPS +24%
FY26 guidance was revised down in April 2026 (Q1 earnings) from initial February guide:
- Organic growth: 10–11% → 6.5–8.0%
- Adjusted EPS: $3.43–3.49 → $3.34–3.41
The downward revision triggered a -18% stock reaction in Q1 2026. Concerns: PFA market share competition from Medtronic Affera + J&J Varipulse; PulseSelect FDA expansion; EP segment growth deceleration from 37% (Q4 25) to expected mid-teens FY26.
Forward Estimates
FY2026 Guide (revised April 2026):
- Net Sales: ~$22B (+10–11%)
- Organic Growth: +6.5–8.0%
- Adjusted EPS: $3.34–3.41
- FCF: ~$4B
Bull case: FARAPULSE share defends 38%+ against Medtronic Affera + J&J Varipulse; Bolt Medical IVL adds incremental growth; international EP expansion accelerates; multiple recovers to 38–40x P/E. Bear case: FARAPULSE share erosion to 25–30% over 2026–27; PFA category commoditizes; revenue growth decelerates to single-digit FY27; multiple compresses to 25x P/E. Consensus targets $130–145 vs. trading ~$105–115 (~20–35% implied upside post Q1 sell-off).
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $BSX.